Joel Randolph Hecht

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
PURPOSE BRAF V600E mutation is seen in 5% to 8% of patients with metastatic colorectal cancer (CRC) and is associated with poor prognosis. Vemurafenib, an oral BRAF V600 inhibitor, has pronounced activity in patients with metastatic melanoma, but its activity in patients with BRAF V600E-positive metastatic CRC was unknown. PATIENTS AND METHODS In this(More)
  • 1